KALETRA Drug Patent Profile

Which patents cover Kaletra, and what generic alternatives are available?

Kaletra is a drug marketed by Abbvie and is included in three NDAs.

The generic ingredient in KALETRA is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kaletra

A generic version of KALETRA was approved as lopinavir; ritonavir by HETERO LABS LTD III on June 4^th, 2021.

Summary for KALETRA

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	152
Drug Prices:	Drug price information for KALETRA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KALETRA
What excipients (inactive ingredients) are in KALETRA?	KALETRA excipients list
DailyMed Link:	KALETRA at DailyMed

See drug prices for KALETRA

Recent Clinical Trials for KALETRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Oregon Health and Science University	Phase 2
OHSU Knight Cancer Institute	Phase 2
October 6 University	Phase 4

See all KALETRA clinical trials

Pharmacology for KALETRA

Drug Class

Cytochrome P450 3A Inhibitor Protease Inhibitor

Mechanism of Action

Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors P-Glycoprotein Inhibitors UDP Glucuronosyltransferases Inducers

Paragraph IV (Patent) Challenges for KALETRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KALETRA	Oral Solution	lopinavir; ritonavir	80 mg/20 mg per mL	021251	1	2014-06-19
KALETRA	Tablets	lopinavir; ritonavir	100 mg/25 mg and 200 mg/50 mg	021906	1	2008-12-23

US Patents and Regulatory Information for KALETRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	KALETRA	lopinavir; ritonavir	CAPSULE;ORAL	021226-001	Sep 15, 2000		DISCN	No	No
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-001	Oct 28, 2005	AB	RX	Yes	Yes
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251-001	Sep 15, 2000		RX	Yes	Yes
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-002	Nov 9, 2007	AB	RX	Yes	No

Expired US Patents for KALETRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251-001	Sep 15, 2000

EU/EMA Drug Approvals for KALETRA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Lopinavir/Ritonavir Mylan	lopinavir, ritonavir	EMEA/H/C/004025Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.	Authorised	yes	no	no	2016-01-14
AbbVie Deutschland GmbH Co. KG	Kaletra	lopinavir, ritonavir	EMEA/H/C/000368Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.	Authorised	no	no	no	2001-03-19

International Patents for KALETRA

See the table below for patents covering KALETRA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	143262
Austria	168677
Austria	196761
Austria	213733
Austria	230402

Supplementary Protection Certificates for KALETRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0674513	C00674513	Switzerland		PRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213
0674513	SPC/GB01/044	United Kingdom		PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
0674513	C300060	Netherlands		PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320

Last updated: July 22, 2026

KALETRA (lopinavir/ritonavir) Market Dynamics and Financial Trajectory: Pricing, Volume, Exclusivity, and Competitive Pressure

Executive summary: KALETRA (lopinavir/ritonavir; AbbVie) has shifted from a dominant first-line protease inhibitor to a declining antiretroviral anchored mainly in HIV treatment regimens for patients with access constraints, resistance considerations, and specific guideline positioning. Financial trajectory is characterized by: (1) long-run volume erosion from newer, higher-barrier-to-resistance antiretroviral classes and fixed-dose competitors; (2) pricing pressure from generic entry in major markets; (3) uneven geographic persistence in lower-cost and formulary-driven settings; and (4) steady but limited remaining value tied to ongoing supply of older regimens rather than new uptake.

---

How has KALETRA’s HIV market share evolved since launch?

KALETRA entered the market as a backbone protease inhibitor (PI) regimen for HIV-1 treatment. Over time, the market moved toward integrase strand transfer inhibitors (INSTIs) and later toward regimens with improved tolerability and simplified dosing, which compressed the addressable PI segment.

What drove long-run demand decline for lopinavir/ritonavir?

Key structural demand headwinds:

• Class shift toward INSTIs: Regimens anchored on dolutegravir, bictegravir, and other INSTIs displaced many PI-based starts.
• Tolerability and pill-burden: KALETRA’s formulation and dosing requirements became less competitive versus newer fixed-dose therapies.
• Metabolic side-effect profile: PI-associated lipid and metabolic effects reduced preference in guideline-driven choices.
• Resistance management changes: Modern salvage strategies more often use drug classes with stronger resistance profiles and higher barriers.

Where did KALETRA retain share longer?

KALETRA remained more persistent in:

• Settings with constrained access to newer agents.
• Patients with documented resistance patterns where PI activity remained clinically relevant.
• Institutional formularies with established procurement and contracted pricing.

---

What is the competitive landscape for KALETRA today?

KALETRA competes against:

1. INSTI-based fixed-dose combinations (first-line and many second-line settings).
2. Other boosted PIs in select salvage or constrained access scenarios (brand and generic).
3. Generic lopinavir/ritonavir once local regulatory and commercial thresholds allowed broader generic penetration.

How do competitors typically win access against KALETRA?

• Lower or negotiated net pricing through generics for lopinavir/ritonavir and through branded INSTI regimens where affordability programs apply.
• Better convenience: once-daily and single-tablet regimens.
• Stronger guideline preference for modern classes, affecting prescribing behavior and procurement priorities.

---

When does KALETRA lose exclusivity and what does that mean for revenue?

KALETRA’s market impact is dominated by generic erosion rather than near-term patent life in many jurisdictions. As generic lopinavir/ritonavir became available, revenue became primarily a function of:

• remaining protected brand use in certain geographies and tender structures, and
• contracting choices that delay switching or maintain brand supply.

How do exclusivity expirations typically translate into financial decline for an older HIV brand?

• Pricing collapse after generic entry.
• Formulary switching in national procurement cycles.
• Brand share retention only where supply chain, tender terms, or procurement contracts delay substitution.

---

What is the Orange Book status of KALETRA and how does that affect generic risk?

KALETRA is not primarily a “new drug exclusivity” story in the way modern small molecules are assessed. Instead, the dominant generic-risk channel is litigation history and generic approvals across dosage forms, which historically reduced brand economics quickly once substitution became feasible.

Dosage forms and substitution dynamics

KALETRA has been marketed in multiple formulations over time, which affects:

• replacement timing in formularies,
• interchangeability where regulators allow,
• and buyer switching behavior based on local availability.

(No Orange Book filing-level mapping is provided here because the request is market dynamics and financial trajectory rather than claim-by-claim freedom-to-operate.)

---

How many generic versions of lopinavir/ritonavir are on the market and what is the pricing impact?

Generic penetration for lopinavir/ritonavir generally produces a durable price compression:

• Net price declines quickly after generic entry.
• Brand-to-generic substitution depends on tender cycles, existing contracts, and supply reliability.

Financial consequence for AbbVie

• AbbVie’s KALETRA brand revenue becomes increasingly net-deflationary even if absolute demand remains stable in some regions.
• The remaining value shifts toward managed access procurement and brand-replacement delays.

---

What patent estate barriers (formulation, method-of-use) affect KALETRA generics?

For older HIV PIs, patent estates typically matter less than they do for late-stage biologics or newer small-molecule launches because:

• many primary composition and formulation concepts have aged,
• and generic competition is often established through market clearance pathways.

Where relevant, remaining barriers usually relate to:

• specific formulation technologies (drug product and stability-related claims),
• and regimen-specific method claims (where enforceable against induced infringement).

(This section focuses on the commercial mechanics; no claim-level patent list is provided because the request is market and financial trajectory.)

---

What drug product economics matter most for KALETRA revenue?

KALETRA economics are driven by:

1. Net price per patient per month (after rebates and tender pricing).
2. Share of prescriptions in PI-sparing regimens.
3. Geographic mix (brand retention in certain tenders vs generic dominance elsewhere).
4. Dosing conversion (liquid vs tablets, pediatric vs adult use patterns).
5. Contract duration in public procurement and hospital formularies.

How do reimbursement and procurement cycles shape quarterly revenue?

• Revenue tends to be “lumpy” around tender awards and renewal dates.
• Generic switchovers cause abrupt declines, while brand persists where contracts run longer.

---

Which regions have the highest remaining demand for KALETRA?

Remaining demand is shaped by:

• national HIV program formularies,
• price bands and generic procurement policies,
• availability of alternative INSTI therapies,
• and the resistance landscape in patient cohorts.

Common pattern for older antiretrovirals:

• Higher persistent usage in regions with procurement continuity and constrained newer drug adoption.
• More rapid erosion where INSTI availability and local procurement switching are faster.

---

How does KALETRA compare with newer HIV therapies in cost-effectiveness terms?

In most guideline-driven and payer-driven contexts:

• Newer INSTI-based regimens are preferred due to improved tolerability and simplified regimens.
• Even when PI-based regimens can be clinically viable, cost-effectiveness shifts toward regimens that reduce adverse-event management and simplify adherence.

For KALETRA specifically, cost-effectiveness degrades when:

• patients face PI-associated metabolic or GI effects,
• adherence costs rise with dosing complexity,
• and switching to INSTI regimens becomes feasible.

---

What settlement or litigation events have historically shaped KALETRA’s market?

For older HIV drugs, litigation historically impacts:

• timing of generic market entry,
• scope of generic approvals,
• and sometimes product-form substitution.

However, the long-run market outcome is usually:

• generic entry compresses pricing quickly, and
• brand revenue becomes largely a function of residual protected use and contract timing.

(No specific case docket or settlement agreement list is provided because the prompt targets market dynamics and financial trajectory rather than litigation mapping.)

---

How does biosimilar risk apply to KALETRA?

KALETRA is a small-molecule antiretroviral, not a biologic. Biosimilar frameworks do not apply.

---

What are the main remaining commercial levers for KALETRA?

For an older HIV brand facing generic dominance, levers typically include:

• regional tender strategy and managed access supply arrangements,
• patient cohort retention (resistance-driven PI persistence),
• pediatric and specific formulation continuity where switches are slower,
• and manufacturing reliability for ongoing supply.

---

What does the financial trajectory imply for AbbVie’s HIV portfolio planning?

The KALETRA story implies:

• Protease inhibitors are increasingly portfolio-retention products rather than growth drivers.
• AbbVie’s HIV growth focus is structurally tied to newer regimens and life-cycle management in adjacent drug classes rather than continued expansion of legacy PI economics.

---

Key Takeaways

• KALETRA’s market trajectory is dominated by class displacement to INSTI-based regimens and generic lopinavir/ritonavir price erosion.
• Brand value increasingly depends on geographic procurement frictions, contract timing, and cohort-specific clinical needs rather than new uptake.
• The financial pattern for older HIV brands typically shifts from growth to net-price decline with slower demand substitution, producing a prolonged but compressed revenue stream.
• Competitive pressure is persistent: improved tolerability and simplified dosing in newer regimens continue to reduce PI share over time.

---

FAQs

1. Why did lopinavir/ritonavir lose market share to INSTI-based regimens?
   Improved tolerability, simpler dosing, and stronger guideline preference for INSTI anchors.

2. Do generic lopinavir/ritonavir products usually eliminate KALETRA brand revenue?
   They compress price and share, but brand revenue may persist in limited geographies and contract-bound formularies.

3. What patient groups are most likely to remain on KALETRA?
   Patients with resistance patterns or clinical scenarios where PI activity remains relevant and alternatives are not immediately feasible.

4. Is KALETRA exposed to biosimilar competition?
   No. It is not a biologic.

5. What procurement factors most affect KALETRA’s quarterly sales volatility?
   Tender award timing, renewal cycles, and interchangeability rules for formulations in public programs and hospital formularies.

---

References

No sources were cited in the provided response.